争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 4 条
2026
法国在出现死亡关联后召回Tavneos批次
宣布召回
法国药品安全机构ANSM表示，法国境内所有Tavneos批次将于8月19日开始召回。该药由美国生物技术公司安进生产，并由全球不同合作伙伴药企销售，此前在日本被指与20例死亡相关。欧盟委员会本月早些时候已撤销该药的上市许可。
品牌回应
召回 — France's medicine safety agency ANSM
"The recall of all batches available in France will begin on August 19," France's medicine safety agency ANSM said in a statement.
来源摘录
The European Commission revoked the drug's marketing authorisation earlier this month because "the benefits are no longer proven to outweigh its risks".
Kissei Pharmaceutical, which sells the drug in Japan, said in May that 20 deaths had been reported among people using the it since 2022.
A drug called Tavneos used to treat rare autoimmune diseases will be pulled from the shelves in France, the country's medicine watchdog said Wednesday, after it was linked to 20 deaths in Japan.
2022
Lindis Biotech 就专利问题起诉安进
提起诉讼
Lindis Biotech 在特拉华州联邦地区法院起诉安进，指控安进侵犯了三项与免疫疗法方案有关的专利。诉状请求法院认定侵权并判赔等；报道未表明法院已作出认定。
来源摘录
The plaintiffs are seeking a declaration that Amgen infringed upon the ‘421, ‘158 and ‘149 patents, actual damages, interest, attorney’s fees and costs, and other relief.
On Monday, Lindis Biotech, GmbH filed a complaint in the District of Delaware against Amgen Inc. for allegedly infringing upon their patents for an immunotherapy regimen that is more effective, and less harmful to the human body, than chemotherapy or radiation treatments.
2021
安进在专利争议中向美国最高法院提交请愿书
提起诉讼
Amgen Inc.及其子公司向美国最高法院提交调卷令请愿书，所涉对方为Sanofi Aventisub LLC、Regeneron Pharmaceuticals Inc.和Sanofi-Aventis US, LLC。请愿书涉及专利书面描述要求及其所需的详细程度。
来源摘录
On Monday a petition for certiorari was filed to the Supreme Court of the United States by Amgen Inc. and its subsidiaries against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC.
2012